RAS at 40: Update from the RAS Initiative
Dwight V Nissley1, Frank McCormick2
1Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Summary:
The RAS Initiative was launched in 2013 to address unmet clinical needs of patients with KRAS-driven cancers. The Initiative is based at Frederick National Laboratory for Cancer Research in Frederick, MD, and involves multiple collaborations with the RAS research community in academia and industry with the shared goal of developing RAS therapies.
Insights
The RAS Initiative aims to develop new therapies for KRAS-driven cancers, addressing critical unmet patient needs. This collaborative effort unites researchers to advance treatment options for these challenging malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- KRAS-driven cancers represent a significant unmet clinical need.
- Targeting RAS pathways is crucial for effective cancer therapy.
Purpose of the Study:
- To establish and coordinate a research initiative focused on RAS-driven cancers.
- To foster collaborations for the development of novel RAS therapies.
Main Methods:
- The RAS Initiative was launched in 2013.
- It is based at Frederick National Laboratory for Cancer Research.
- It involves collaborations with academic and industry researchers.
Main Results:
- The initiative has brought together a diverse research community.
- Progress has been made in understanding RAS biology and identifying therapeutic targets.
Conclusions:
- The RAS Initiative is actively working towards developing new treatments for patients with KRAS-driven cancers.
- Continued collaboration is essential for advancing RAS-targeted therapies.
Related Concept Videos
The Ras Gene
Ras is a...
Abnormal Proliferation
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Longitudinal Research
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
MAPK Signaling Cascades


